Takeshi Akiyoshi

Takeshi Akiyoshi

Auto-generated profile, based on publicly available information

Takeshi Akiyoshi

Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen Minato-ku, Tokyo, 105-8512, Japan; Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan; School of Medicine, Keio University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
YYYuki Yamaguchi
Yuki Yamaguchi
TATakeshi Akiyoshi
Takeshi Akiyoshi
GKGo Kawamura
Go Kawamura
AIAyuko Imaoka
Ayuko Imaoka
MMMitsue Miyazaki
Mitsue Miyazaki
HOHisakazu Ohtani
Hisakazu Ohtani
Cytochrome P450 (CYP) 3A4 is one of the major drug-metabolizing enzymes. Genetic variants of CYP3A4 with altered activity are one of the factors responsible for interindividual differences in drug metabolism. Azole antifungals inhibit CYP3A4 to cause clinically significant drug-drug interactions. In the present quantitative study, we investigated the inhibitory effects of three azole antifungals (ketoconazole, voriconazole, and fluconazole) on testosterone metabolism by recombinant CYP3A4 genetic variants (CYP3A4.1 (WT), CYP3A4.2, CYP3A4.7, CYP3A4.16, and CYP3A4.18) and compared them with those previously reported for itraconazole. The inhibition constants (Ki) of ketoconazole, voriconazole, and fluconazole for rCYP3A4.1 were 3.6 nM, 3.2 μM, and 16.1 μM, respectively. The Ki values of these azoles for rCYP3A4.16 were 13.9-, 13.6-, and 6.2-fold higher than those for rCYP3A4.1, respectively, whereas the Ki value of itraconazole for rCYP3A4.16 was 0.54-fold of that for rCYP3A4.1. The other genetic variants had similar effects on the Ki values of the three azoles, whereas a very different pattern was seen for itraconazole. In conclusion, itraconazole has unique characteristics that are distinct from those shared by the other azole anti-fungal drugs ketoconazole, voriconazole, and fluconazole with regard to the influence of genetic variations on the inhibition of CYP3A4.

1 April 2020 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TMTokio Morita
Tokio Morita
TATakeshi Akiyoshi
Takeshi Akiyoshi
RSRyo Sato
Ryo Sato
KKKazuhiro Katayama
Kazuhiro Katayama
KYKodai Yajima
Kodai Yajima
HOHisakazu Ohtani
Hisakazu Ohtani

1 December 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
RSRyo Sato
Ryo Sato
TATakeshi Akiyoshi
Takeshi Akiyoshi
TMTokio Morita
Tokio Morita
KKKazuhiro Katayama
Kazuhiro Katayama
KYKodai Yajima
Kodai Yajima
HOHisakazu Ohtani
Hisakazu Ohtani

8 November 2017 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
KYKeiichi Yotsumoto
Keiichi Yotsumoto
TATakeshi Akiyoshi
Takeshi Akiyoshi
NWNaoki Wada
Naoki Wada
AIAyuko Imaoka
Ayuko Imaoka
HOHisakazu Ohtani
Hisakazu Ohtani

1 February 2022 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TATakeshi Akiyoshi
Takeshi Akiyoshi
MUMarika Uchiyama
Marika Uchiyama
RIRino Inada
Rino Inada
AIAyuko Imaoka
Ayuko Imaoka
HOHisakazu Ohtani
Hisakazu Ohtani

14 May 2018 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
AIAyuko Imaoka
Ayuko Imaoka
KAKosuke Abiru
Kosuke Abiru
TATakeshi Akiyoshi
Takeshi Akiyoshi
HOHisakazu Ohtani
Hisakazu Ohtani
Intestinal absorption of new quinolones is decreased by oral administration of polyvalent metal cations. Some clinical studies have demonstrated this drug - drug interaction is more prominent under fasted condition. However, the effect of food intake on the extent of drug - drug interaction between new quinolones and metal cations remains to be investigated quantitatively and systematically. The aim of this study was to develop an animal model that enables to evaluate the effect of food intake on the extent of drug - drug interaction in the gastrointestinal tract by chelation and to apply the model to evaluate quantitatively the effect of food intake on the drug - drug interaction between two new quinolones, ofloxacin or ciprofloxacin and sucralfate. The rats were orally administered new quinolones (5.3 mg/kg of ofloxacin or 10 mg/kg of ciprofloxacin) with or without 13.3 mg/kg of sucralfate under fasted or fed condition and plasma concentration profiles of new quinolones were monitored. To the fed group, standard breakfast used in human studies was pasted and administered at a dose of 8.8 g/kg. The area under the plasma concentration - time curves (AUC0–6) of ofloxacin and ciprofloxacin under the fasted condition were significantly decreased to 28.8 and 17.1% by co-administration of sucralfate, respectively. On the contrary, sucralfate moderately decreased the AUC0–6 of ofloxacin and ciprofloxacin to 54.9 and 33.2%, respectively, under fed condition. The effects of sucralfate and food intake on the kinetics of ofloxacin in this study were well consistent with the results of previous clinical trial. The developed animal model quantitatively reproduced the effect of food intake on the drug - drug interaction between ofloxacin and sucralfate. The similar influences were observed for the drug - drug interaction between ciprofloxacin and sucralfate, suggesting that the extent of drug - drug interaction caused by chelation is generally attenuated by food intake.